Drug Trial News

RSS

Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine

VaxOnco, a leading oncology biopharmaceutical company, today announced that following FDA IND approval, it will sponsor a Phase I folate receptor alpha-targeted therapeutic vaccine clinical trial in disease-free patients, previously diagnosed with either breast or ovarian cancer at Mayo Clinic.

25 Jul 2011

R-Tech Ueno announces protocol amendment of RK-023 Phase I trial for eyelash hypotrichosis

R-Tech Ueno is pleased to announce protocol amendment of a Phase I Clinical Study of RK-023, a new compound being developed for the treatment of hypotrichosis of the eyelashes.

25 Jul 2011

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.

22 Jul 2011

Enrollment begins in Repligen's RG1068 pilot study to improve detection, staging of pancreatic cancer

Repligen Corporation today announced that the first patient has been enrolled in a pilot study to evaluate the ability of RG1068 to improve detection and characterization of pancreatic cancer in combination with contrast-enhanced magnetic resonance imaging (MRI) and computed tomography.

22 Jul 2011

UK regulators approve Europe's first clinical trial of plant-derived antibody for HIV

UK regulators have approved Europe's first clinical trial of a monoclonal antibody produced from genetically modified plants. This landmark decision sets the stage for the testing, in humans, of an anti-HIV product made from genetically modified tobacco plants. It will open the door for trials of additional plant-derived medicines treating a range of diseases.

22 Jul 2011

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama.

22 Jul 2011

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

Inotek Pharmaceuticals Corp., a leader in the development of innovative medicines to address significant diseases of the eye, today announced that the Company has successfully completed the first two of three stages of a multiple-dose Phase 2b clinical trial of its novel eye-drop candidate, INO-8875, in patients with glaucoma or ocular hypertension.

22 Jul 2011

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

BioSante Pharmaceuticals, Inc., today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening medical conditions and significant disabilities.

21 Jul 2011

Isis commences ISIS-PTP1BRx Phase 1 study in type 2 diabetes

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B.

21 Jul 2011

PAREXEL completes 100th Asian ethnobridging study

PAREXEL International Corporation, a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.

From Parexel 21 Jul 2011

Clinical Vaccine Immunology publishes NanoBio's NB-1008 influenza study results

NanoBio Corporation announced today that data from its ferret influenza vaccine study of NB-1008 have been published in the July 2011 issue of Clinical Vaccine Immunology by the American Society of Microbiology.

21 Jul 2011

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

21 Jul 2011

Clinical study of anti-HIV antibody made from genetically modified tobacco plants

Pharmaceuticals can be produced by plants. Antibodies that have been produced in tobacco plants will now for the first time be tested in a clinical study.

21 Jul 2011

Boosted REYATAZ shows durable viral suppression in women with HIV

Bristol-Myers Squibb Company announced results from a long-term, retrospective, European cohort study, which included 1,294 antiretroviral (ARV)-experienced patients from Germany, France and Sweden, that were presented today at the Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

21 Jul 2011

Bristol-Myers Squibb announces results of BMS-708163 Phase II study on Alzheimer's

Bristol-Myers Squibb Company today announced the results of a Phase II study evaluating the safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer's disease.

21 Jul 2011

Promising results from phase I study of Genentech's GDC-0941 for advanced breast cancer

A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology.

21 Jul 2011

Final SVR results from Pharmasset's PSI-7977 phase 2b study in HCV

Pharmasset, Inc. announced today the final sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 dosed once daily in combination with peginterferon alfa 2a and ribavirin in subjects with hepatitis C virus (HCV) genotype 2 or 3 who have not been treated previously.

20 Jul 2011

Three-drug regimen more effective for treating H. pylori infection

Helicobacter pylori, the bacterium known to cause peptic ulcers, is also the primary cause of gastric cancer, which is a leading cancer killer globally.

20 Jul 2011

NCCN experts recommend bevacizumab for treating metastatic breast cancer

The Expert Breast Cancer Panel of the National Comprehensive Cancer Network (NCCN) met July 10-12, 2011 in Philadelphia, PA. At the meeting, the multidisciplinary breast cancer experts voted in favor of maintaining the current position and recommendation in the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer on the use of bevacizumab in metastatic breast cancer.

20 Jul 2011

Chemotherapy combined with anti-cancer agent shows promise for treatment of aggressive breast cancers

Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

20 Jul 2011

Drug Trial News

Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine

R-Tech Ueno announces protocol amendment of RK-023 Phase I trial for eyelash hypotrichosis

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

Enrollment begins in Repligen's RG1068 pilot study to improve detection, staging of pancreatic cancer

UK regulators approve Europe's first clinical trial of plant-derived antibody for HIV

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

Isis commences ISIS-PTP1BRx Phase 1 study in type 2 diabetes

PAREXEL completes 100th Asian ethnobridging study

Clinical Vaccine Immunology publishes NanoBio's NB-1008 influenza study results

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Clinical study of anti-HIV antibody made from genetically modified tobacco plants

Boosted REYATAZ shows durable viral suppression in women with HIV

Bristol-Myers Squibb announces results of BMS-708163 Phase II study on Alzheimer's

Promising results from phase I study of Genentech's GDC-0941 for advanced breast cancer

Final SVR results from Pharmasset's PSI-7977 phase 2b study in HCV

Three-drug regimen more effective for treating H. pylori infection

NCCN experts recommend bevacizumab for treating metastatic breast cancer

Chemotherapy combined with anti-cancer agent shows promise for treatment of aggressive breast cancers

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News